Abstract 5558
Background
TALA is a potent PARP inhibitor. Efficacy and safety profiles of once-daily TALA 1 mg were established in advanced breast cancer patients (pts) in the phase 3 EMBRACA and phase 2 ABRAZO trials. Approximately 60% of pts experience dose modification due to an adverse event (AE). This analysis characterized the relationship between TALA exposure and grade 3 or higher anemia, neutropenia, and thrombocytopenia, the most common AEs leading to dose modification.
Methods
Safety and pharmacokinetic (PK) data from 367 TALA-treated pts (285 EMBRACA, 82 ABRAZO) were included in a pooled analysis. To account for dose modifications over time, individual time-varying concentration from time 0 up to the time of each safety event (Cavg,t) was calculated at each event time using average daily dose intensity and apparent TALA clearance as obtained from population PK analysis. The relationship between Cavg,t, as well as other potential prognostic factors and the selected safety events was evaluated using Cox proportional hazard (PH) models. Significant covariates in univariate analyses were further examined in multi-variate analyses.
Results
Visual examination suggested a higher Cavg,t in pts with anemia and thrombocytopenia events vs pts without events. Cox PH models indicated that a higher risk of anemia and thrombocytopenia was associated with higher Cavg,t. For anemia, the HR (95% CI) for Cavg,t (ng/mL) was 1.3 (1.12, 1.4), P = 3.03. For thrombocytopenia, the HR (95% CI) for Cavg,t (ng/mL) was 1.2 (1.01, 1.3), P = 0.0394. A trend for association between higher Cavg,t and neutropenia was observed although the relationship was not statistically significant (P = 0.0633). Higher risk of all tested safety endpoints was associated with lower baseline hemoglobin. Higher risk of neutropenia was associated with lower absolute neutrophil count and lower body weight.
Conclusions
A higher risk of anemia and thrombocytopenia was associated with higher TALA exposure. This finding supports the proposed management of TALA-related AEs through dosing interruption and reduction.
Clinical trial identification
NCT01945775, NCT02034916.
Legal entity responsible for the study
Pfizer, Inc.
Funding
Pfizer, Inc.
Editorial Acknowledgement
Editorial and medical writing support funded by Pfizer Inc. were provided by Edwin Thrower, PhD, Mary Kacillas and Paula Stuckart of Ashfield Healthcare Communications, Middletown, Connecticut.
Disclosure
J.K. Litton: Institutional-contracted research: Pfizer, Novartis, EMD-Serono, AstraZeneca, GlaxoSmithKline, and Genentech; Advisory board participation: AstraZeneca and Pfizer, both uncompensated. N.C. Turner: Advisory board, honoraria and research funding: Pfizer and BioMarin. M. Elmeliegy, A. Czibere, Y. Yu, G.G. Wilson, I.C. Tudor, J. Zheng, D.D. Wang: Employment: Pfizer, Inc.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract